药明生物（2269.HK）股价与投研分析
WuXi Biologics · 香港市场 · 医药健康
关键指标
- 最新价
- HKD 48.68
- 日内涨跌
- +0.75%
- 市值
- HKD 2004.04 亿
- 市盈率 TTM
- 36.88
- 市净率
- 3.54
- 52 周最高
- HKD 58.00
- 52 周最低
- HKD 28.48
- 股息率
- 0.00%
- 成交量
- 股 4694.93 万
- 上市市场
- 香港
公司概况
药明生物（英文名 WuXi Biologics，股票代码 2269.HK）在香港市场上市， 属于医药健康行业，当前处于成长阶段。核心标签：CXO、生物药、CDMO。
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens (TAA) mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
AI 三层投研框架
- 宏观周期层：利率、通胀、汇率与流动性如何影响香港市场的估值中枢。
- 行业格局层：用 PEST、波特五力与产业链位置判断医药健康行业的利润分配。
- 公司质地层：把 药明生物 的增速、利润率、ROE 与现金流放进同行业横向对比。
需要完整报告？回到终端 可基于真实财报数据生成三层 AI 分析。